Physician profile
Jaimee Kamp
NPI 1346631496
$2,786.82
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $954 · 2023: $1,053 · 2024: $64.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.07 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.27 | 2021-2023 | |
| Janssen Biotech, INC. | $286.92 | 2021-2024 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $279.52 | 2021-2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $233.89 | 2021-2023 | |
| Genzyme Corporation | $208.66 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $189.77 | 2021-2023 | Ilumya |
| Amgen INC. | $97.53 | 2021-2023 | Otezla |
| Almirall LLC | $74.15 | 2021-2023 | Seysara |
| Ucb, INC. | $68.97 | 2021-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $67.45 | 2023 | Sotyktu |
| Lilly USA, LLC | $65.30 | 2021-2023 | Olumiant, Taltz |
| Leo Pharma INC. | $58.70 | 2021-2023 | Adbry |
| Incyte Corporation | $58.07 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $32.94 | 2023 | |
| Merz Pharmaceuticals, LLC | $23.08 | 2023 | Xeomin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2023 | Cyltezo |
| Pfizer INC. | $17.81 | 2023 | |
| Genentech USA, INC. | $17.61 | 2023 | Xolair |
| Organogenesis INC. | $16.28 | 2023 | Puraply |
| Dermavant Sciences, INC. | $15.19 | 2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaimee Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.